Novartis Seen Gaining as Merck Scraps MS Drug

Novartis's chances of eventually dominating the multibillion dollar multiple-sclerosis market with its new Gilenya pill got a boost when Merck of Germany abandoned attempts to market a rival treatment.

AstraZeneca Sells Dental Unit

AstraZeneca said it has agreed to sell Astra Tech to Dentsply International for $1.8 billion, after a sale process that attracted strong interest from private-equity firms and strategic buyers.

Lupin Expects Better Operating Margin in Two Years

Lupin may find it tough to improve its operating margin this fiscal year through March, but the Indian generic drug maker's profitability is expected to jump in a couple of years, helped mainly by the launch of several lucrative products in the U.S. and lower research costs.

Pharma Firm Injects Life

A new Boston headquarters for drug manufacturer Vertex Pharmaceuticals is one of the largest private construction projects to move forward since the recession.

FDA Panel Votes Against Gout Drug

Walgreen, Express Scripts in Spat

High Court Will Hear Appeal by Mayo Clinic

High Court Rejects Wyeth Appeal